MENU
+Compare
FOLD
Stock ticker: NASDAQ
AS OF
Nov 20, 02:21 PM (EDT)
Price
$9.58
Change
-$0.15 (-1.54%)
Capitalization
3B

FOLD Amicus Therapeutics Forecast, Technical & Fundamental Analysis

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases... Show more

Industry: #Biotechnology
FOLD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for FOLD with price predictions
Nov 19, 2025

Momentum Indicator for FOLD turns positive, indicating new upward trend

FOLD saw its Momentum Indicator move above the 0 level on October 20, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for FOLD just turned positive on October 22, 2025. Looking at past instances where FOLD's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FOLD advanced for three days, in of 285 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 168 cases where FOLD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FOLD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

FOLD broke above its upper Bollinger Band on November 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. FOLD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.021) is normal, around the industry mean (27.606). P/E Ratio (0.000) is within average values for comparable stocks, (52.154). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.053). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (4.998) is also within normal values, averaging (329.190).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FOLD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
FOLD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

FOLD is expected to report earnings to rise 16.67% to 7 cents per share on February 19

Amicus Therapeutics FOLD Stock Earnings Reports
Q4'25
Est.
$0.07
Q3'25
Beat
by $0.03
Q2'25
Beat
by $0.12
Q1'25
Beat
by $0.05
Q4'24
Beat
by $0.08
The last earnings report on November 04 showed earnings per share of 5 cents, beating the estimate of 2 cents. With 828.83K shares outstanding, the current market capitalization sits at 3.00B.
A.I. Advisor
published General Information

General Information

a developer of orally active drugs to treat human genetic diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
47 Hulfish Street
Phone
+1 609 662-2000
Employees
517
Web
https://www.amicusrx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IRLIX44.74N/A
N/A
Voya Russell Large Cap Index Port A
PAMCX93.92N/A
N/A
T. Rowe Price Mid-Cap Growth Adv
LGCRX19.25N/A
N/A
Lord Abbett Global Equity R3
LFVAX24.94N/A
N/A
Lord Abbett Focused Small Cap Value A
BDBKX26.07-0.01
-0.04%
iShares Russell 2000 Small-Cap Idx K

FOLD and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, FOLD has been loosely correlated with BMRN. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if FOLD jumps, then BMRN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FOLD
1D Price
Change %
FOLD100%
+1.41%
BMRN - FOLD
46%
Loosely correlated
-2.95%
RARE - FOLD
45%
Loosely correlated
-2.99%
XNCR - FOLD
44%
Loosely correlated
-1.62%
ARWR - FOLD
44%
Loosely correlated
-3.71%
VCYT - FOLD
43%
Loosely correlated
+3.02%
More